Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

4 terminated/withdrawn out of 14 trials

Success Rate

63.6%

-22.9% vs industry average

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(45.5%)

N/A

2(18.2%)

Phase 1

2(18.2%)

Phase 3

2(18.2%)

11Total

Phase 2(5)

N/A(2)

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT00000739Phase 1Completed

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Role: collaborator

NCT00000640Phase 3Completed

A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS

Role: collaborator

NCT00001028Phase 3Completed

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

Role: collaborator

NCT02012933Unknown

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Role: collaborator

NCT00704925Unknown

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Role: collaborator

NCT00994916Unknown

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Role: collaborator

NCT02090725Phase 2Terminated

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

Role: collaborator

NCT00495521Phase 2Terminated

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

Role: lead

NCT01511978Phase 2Completed

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Role: lead

NCT00417690Phase 2Terminated

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

Role: lead

NCT00429533Phase 2Terminated

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

Role: lead

NCT00002043Not ApplicableCompleted

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Role: lead

NCT00002283Not ApplicableCompleted

A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Role: lead

NCT00002120Phase 1Completed

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

Role: collaborator

All 14 trials loaded